MicuRx Taps China Links To Progress Improved Oxazolidinone
This article was originally published in PharmAsia News
Multidrug-resistant bacteria have been identified as a major public health threat by the WHO. MicuRx, a Sino-US drug developer, is discovering and developing novel potential first-in-class antibiotics to combat such infections, and is taking an oxazolidinone with expected benefits over same class drugs into Phase III China trials.
Register for our free email digests: